Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PARIS, 03 déc. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actionscomposant le capital socialNombre total de droits de...
-
PARIS, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
-
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in...
-
Applied StemCell uses TARGATT™ tech to insert a 50 kb multifunctional DNA construct into hiPSCs, enabling development of allogeneic iPSC-based therapies.
-
Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel...
-
Pluristyx signs key clinical use licenses for its iPSC platform, enabling new regenerative and neurological disease therapies.
-
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose...
-
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
-
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to...
-
○ Efficacité : taux de réponse global (ORR) de 68 % avec le Process 2 de lasmé-cel (P2) (n=22) ; 83 % à la dose recommandée de Phase 2 (RP2D, n=12) ; et 100 % dans la population cible de Phase 2...